Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › DREAMS-2

DREAMS-2

Mazdutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Mazdutide
Population
t2d
Official title
A Study of IBI362 in Participants With Type 2 Diabetes
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
3
Registry status
completed · 2023-01 → 2024-01
Participants
731
Duration
28 weeks
Registry
NCT05606913

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
mazdutide 4 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 %t2d china28——−6.5 %−1.62.18.735.524.05.8—verified
mazdutide 6 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 %t2d china28——−8.5 %−1.73.713.134.429.14.9—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (14)
  • mazdutide 4 mg · weight_tp · Results, Body weight paragraph 1; Table 2
    with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
  • mazdutide 4 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
    TEAEs that led to study treatment discontinuation occurred in five (2.1%) participants who received 4 mg mazdutide
  • mazdutide 4 mg · disc_any · Fig. 1 (trial profile)
    N6[242 received at least one dose] --> N9[21 discontinued study treatment: Adverse event: 5 br Withdrawal by participant: 16]
  • mazdutide 4 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    nausea (35.5%, 34.4% and 17.1%)
  • mazdutide 4 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    vomiting (24.0%, 29.1% and 14.3%)
  • mazdutide 4 mg · sae · Results, Safety paragraph 1; Table 3
    adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
  • mazdutide 4 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
    mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
  • mazdutide 6 mg · weight_tp · Results, Body weight paragraph 1; Table 2
    with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
  • mazdutide 6 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
    nine (3.7%) who received 6 mg mazdutide and four (1.6%) who received 1.5 mg dulaglutide (Table 3 and Extended Data Table 2)
  • mazdutide 6 mg · disc_any · Fig. 1 (trial profile)
    N7[244 received at least one dose] --> N12[32 discontinued study treatment: Adverse event: 9 br Withdrawal by participant: 22 br Physician decision: 1]
  • mazdutide 6 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    nausea (35.5%, 34.4% and 17.1%)
  • mazdutide 6 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
    vomiting (24.0%, 29.1% and 14.3%)
  • mazdutide 6 mg · sae · Results, Safety paragraph 1; Table 3
    adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
  • mazdutide 6 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
    mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: DREAMS-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.